当前位置: X-MOL 学术Acta Pharm. Sin. B › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Erratum: Author correction to 'Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer' [Acta Pharmaceutica Sinica B 2019; 9(5):1061-1077].
Acta Pharmaceutica Sinica B ( IF 14.7 ) Pub Date : 2020-03-26 , DOI: 10.1016/j.apsb.2020.03.003
Dong Mei 1, 2 , Binlong Chen 2 , Bing He 2 , Haibin Liu 3 , Zhiqiang Lin 4 , Jialiang Lin 2 , Xiaoyan Zhang 1 , Ning Sun 1 , Libo Zhao 1 , Xiaoling Wang 1 , Qiang Zhang 2
Affiliation  

The authors regret <that there is an error in Figure 5D “M-combi” group (non-targeting combination group, used as one of the controls) due to the mistake of copying and pasting in the process of assembling pictures. Although it does not affect the conclusion that the active targeting combination group is superior to all other groups, it is an obvious mistake. The authors have now modified Figure 5D as below. Similarly, the fluorescence images of excised organs in Figure 7E “7pep-M-DiR” in single drug group (used as the control group) is repeated with that of Figure 7B “7pep-M-DiR” in single drug group, owing to a copy and paste error during the assembling process. Although it does not change the conclusion that the Combi-cros group is superior to the Combi-simu group (both belong to combined drug group), it is an obvious mistake. The authors have now modified Figure 5D and Figure 7B/7E as follows>.



中文翻译:

勘误:对“用新型转铁蛋白受体靶向的纳米药物主动引发自噬细胞死亡以协同治疗乳腺癌的化学疗法”的作者更正[Acta Pharmaceutica Sinica B 2019; 9(5):1061-1077]。

作者感到遗憾的是,由于组装图片过程中的复制和粘贴错误,图5D“ M-combi”组(非目标组合组,用作控件之一)中出现错误。尽管并不影响主动靶向组合组优于所有其他组的结论,但这是一个明显的错误。作者现在修改了图5D,如下所示。类似地,由于单一药物组(用作对照组)的图7E“ 7pep-M-DiR”中切除的器官的荧光图像与单一药物组中的图7B“ 7pep-M-DiR”的重复荧光图像重复,这是由于组装过程中出现复制和粘贴错误。尽管不能改变Combi-cros组优于Combi-simu组(均属于联合药物组)的结论,但这是一个明显的错误。

更新日期:2020-04-20
down
wechat
bug